Related references
Note: Only part of the references are listed.Sa1204 Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Walid M. Awni et al.
GASTROENTEROLOGY (2015)
Su1218 Concomitant Use of Immunomodulators Increases Long Term Response to Infliximab in Ulcerative Colitis - A Population-Based IBD-Sl Cohort Study
Steven Jeuring et al.
GASTROENTEROLOGY (2015)
Sa1201 Pharmacokinetics of Adalimumab in Pediatric Patients With Moderate to Severe Crohn's Disease
Doerthe Eckert et al.
GASTROENTEROLOGY (2015)
833 Malignancies in Children Receiving Infliximab and Other Inflammatory Bowel Disease Therapies: An Inflammatory Bowel Disease Multicenter, Prospective, Long-Term Registry of Pediatric Patients (Develop) Registry Data
Richard B. Colletti et al.
GASTROENTEROLOGY (2015)
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. G. Levesque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1
Jeffrey S. Hyams et al.
GASTROENTEROLOGY (2014)
Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease
Mark T. Osterman et al.
GASTROENTEROLOGY (2014)
Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
Freddy Cornillie et al.
GUT (2014)
A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease
Elaheh Vahabnezhad et al.
INFLAMMATORY BOWEL DISEASES (2014)
Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease
Peter C. Church et al.
INFLAMMATORY BOWEL DISEASES (2014)
Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis
Uri Kopylov et al.
JOURNAL OF CROHNS & COLITIS (2014)
Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
Charlotte P. Peters et al.
JOURNAL OF CROHNS & COLITIS (2014)
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
F. M. Ruemmele et al.
JOURNAL OF CROHNS & COLITIS (2014)
Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis
Michael J. Hayes et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center
Federica Nuti et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2014)
T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study
Parakkal Deepak et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2013)
Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2013)
Ten Years of Infliximab for Crohn's Disease: Outcome in 469 Patients from 2 Tertiary Referral Centers
Emma J. Eshuis et al.
INFLAMMATORY BOWEL DISEASES (2013)
Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease
Amit Assa et al.
JOURNAL OF CROHNS & COLITIS (2013)
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Orlando Garcia-Bosch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Loss of Response to Long-Term Infliximab Therapy in Children with Crohn's Disease
Oliver Gouldthorpe et al.
PHARMACEUTICALS (2013)
A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
CD14+ intestinal macrophages contribute to the pathogenesis of Crohnʼs disease via IL-23/IFN-gamma axis.
T Hisamatsu et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines
Dan Turner et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2012)
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited
C. I. de Bie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
R. K. Russell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
Lisa J. Herrinton et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Nutritional Status and Growth in Pediatric Crohn's Disease: A Population-Based Study
Francis Vasseur et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
Jeffrey S. Hyams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Harry Sokol et al.
GUT (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease
Joel R. Rosh et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Long-term Outcome of Maintenance Infliximab Therapy in Children with Crohn's Disease
Jeffrey S. Hyoms et al.
INFLAMMATORY BOWEL DISEASES (2009)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children
Jeffrey Hyams et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Share Paper
